Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development

The decades-old cholinergic hypothesis of Alzheimer's disease (AD) led to clinical testing and FDA approval of acetylcholinesterase inhibitor drugs. Subsequently, the α7 nicotinic acetylcholine receptor (α7nAChR) was proposed as a new drug target for enhancing cholinergic neurotransmission. Nea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug development research 2023-09, Vol.84 (6), p.1085-1095
Hauptverfasser:	Burns, Lindsay H, Pei, Zhe, Wang, Hoau-Yan
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylcholine receptors (nicotinic) Acetylcholinesterase Affinity Agonists Allosteric properties Alzheimer's disease Amyloid Biomarkers Biopharmaceuticals Cerebrospinal fluid Cholinergics Cholinesterase inhibitors Clinical trials Cognitive ability Drug development Effectiveness FDA approval Kinases Modulators Neurodegenerative diseases Neuromodulation Neurotransmission Protein interaction Proteins Receptors Tau protein Therapeutic targets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!